Status:
COMPLETED
Evaluation of DiaSorin LIAISON® PTX3 (Long Pentraxin 3) Assay in Patients With Pneumonia
Lead Sponsor:
Diasorin Italia S.p.A.
Conditions:
Pneumonia
Eligibility:
All Genders
18+ years
Brief Summary
LIAISON® PTX3 is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of Long Pentraxin 3 (PTX3) in human plasma samples. LIAISON® PTX3, in conjunction with cli...
Detailed Description
Long Pentraxin 3 (PTX3) is an essential protein of innate immunity, produced by myeloid cells, endothelial cells and respiratory epithelial cells, and involved in resistance to selected pathogens and ...
Eligibility Criteria
Inclusion
- Subjects willing and able to sign the approved Informed Consent form in accordance with international and national regulations
- Patients diagnosed with pneumonia, either CAP, HAP, VAP
- Collection of plasma samples within 24 hours from pneumonia diagnosis (for CAP diagnosis is usually made at ED presentation and for HAP and VAP diagnosis is made during hospital stay)
- K2 EDTA plasma samples dedicated to the study have a minimum volume of 3 mL
Exclusion
- Patients who are currently pregnant
- Samples collected and/or stored in an inappropriate way
Key Trial Info
Start Date :
September 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 29 2024
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT06491004
Start Date
September 20 2021
End Date
March 29 2024
Last Update
July 8 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milan, Italy, 20089
2
Cliniche Humanitas Gavazzeni
Bergamo, Italy, 24125